Yili Lu Pritchett
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yili Lu Pritchett has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Katherine Tracy
Abbott, Abbott Park, IL, USA
1 shared publication - Laura Redden
Abbott, Abbott Park, IL, USA
1 shared publication - Mario Saltarelli
Abbott, Abbott Park, IL, USA
1 shared publication - Mary Garofalo
Abbott, Abbott Park, IL, USA
1 shared publication Roy Tamura
Eli Lilly and Company, Indianapolis, IN, USA
1 shared publication- Weining Robieson
Abbott, Abbott Park, IL, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2011
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 10 (1) , 1
Suicidality and divalproex sodium: analysis of controlled studies in multiple indications
Recent analyses of antiepileptic drugs have indicated an increase in the risk of suicidality. The objective of this report was to provide clinical information and an independent meta-analysis of divalproex sodium and suicidality events by analyzing data from 13 placebo-controlled studies and 1 low-dose controlled study.
- 1 January 2011
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 10 (1) , 1
Open AccessSuicidality and divalproex sodium: analysis of controlled studies in multiple indications
Recent analyses of antiepileptic drugs have indicated an increase in the risk of suicidality. The objective of this report was to provide clinical information and an independent meta-analysis of divalproex sodium and suicidality events by analyzing data from 13 placebo-controlled studies and 1 low-dose controlled study.
- 30 May 2007
- Published by Wiley in Pharmaceutical Statistics
- Vol. 7 (3) , 170-178
Global benefit–risk assessment in designing clinical trials and some statistical considerations of the method
When characterizing a therapy, the efficacy and the safety are two major aspects under consideration. In prescribing a therapy to a patient, a clinician puts the two aspects together and makes a decision based on a consolidated thought process. The global benefit–risk (GBR) measures proposed by Chuang‐Stein et al. (Stat. Med. 1991; 10:1349–1359) are useful in facilitating the thinking, and creating the framework for making statistical comparisons based on benefit–risk point of view. This article describes how a GBR linear score was defined and used as the primary outcome measure in a clinical trial design. The robustness of the definitions of ‘benefit’ and ‘risk’ are evaluated using different criteria. The sensitivity of the pre‐specified weights is also analyzed using alternative weights; one of those was determined by the relative to an identified distribution integral transformation approach (Biometrics 1958; 14:18–38). Statistical considerations are illustrated using pooled data from clinical trials studying antidepressant. The pros and cons for using GBR assessments in the setting of clinical trials are discussed. Copyright © 2007 John Wiley & Sons, Ltd.
- 30 May 2007
- Published by Wiley in Pharmaceutical Statistics
- Vol. 7 (3) , 170-178
Global benefit–risk assessment in designing clinical trials and some statistical considerations of the method
When characterizing a therapy, the efficacy and the safety are two major aspects under consideration. In prescribing a therapy to a patient, a clinician puts the two aspects together and makes a decision based on a consolidated thought process. The global benefit–risk (GBR) measures proposed by Chuang‐Stein et al. (Stat. Med. 1991; 10:1349–1359) are useful in facilitating the thinking, and creating the framework for making statistical comparisons based on benefit–risk point of view. This article describes how a GBR linear score was defined and used as the primary outcome measure in a clinical trial design. The robustness of the definitions of ‘benefit’ and ‘risk’ are evaluated using different criteria. The sensitivity of the pre‐specified weights is also analyzed using alternative weights; one of those was determined by the relative to an identified distribution integral transformation approach (Biometrics 1958; 14:18–38). Statistical considerations are illustrated using pooled data from clinical trials studying antidepressant. The pros and cons for using GBR assessments in the setting of clinical trials are discussed. Copyright © 2007 John Wiley & Sons, Ltd.